

















The implementation of the Nagoya Protocol within surveillance activities



Summary

01

Part 1

Presentation of the overall context

02

Part 2

Ground principles of the Nagoya Protocol

03

Part 3

Practical case: surveillance activities











Part 1

Introduction to the Nagoya Protocol









What is the Nagoya Protocol?

RESEARCH & GENETIC DEVELOPMENT RESOURCES

Conduct of R&D activities on the genetic and/or biochemical composition of genetic resources

Any material of plant, animal, microbial or other origin containing functional units of heredity



Where do surveillance activities stand?

DIAGNOSTIC SURVEILLANCE ACTIVITIES R&D



No international consensus – depends on the country


WHO surveys on the question

Special regime in France





Why has the Nagoya Protocol been adopted?





Why has the Nagoya Protocol been adopted?

MAINN GOAL

PRINCIPLE

CONSEQUENCES

TO FIGHT AGAINST BIOPIRACY



Sovereignty of States over the genetic resources within their territories



ACCESS REQUEST TO GENETIC RESOURCES




BENEFIT-SHARING

IMPACT ON THE COLLECTION, TRANSFER AND USE OF YOUR SAMPLES



Application to all of your activities












Part 2

Ground principles of the Nagoya Protocol










1/4 – Genetic resources

Broad scope: any biological material as a whole or any part of it (e.g. DNA)






Derivatives: antibodies, metabolites, polysaccharides, toxins...

Exclusions: human samples, PIP Framework, international waters...



1/4 – Associated Traditional Knowledge






2/4 – Country of origin's rules application

SABSCH WEBSITE [https://absch.cbd.int/]





2/4 – The Nagoya Protocol within MediLab Secure



PARTY

Nagoya Protocol applies!

NON-PARTY

Nagoya Protocol does NOT apply!





2/4 – The Nagoya Protocol within MediLab Secure

COUNTRY	STATUS	ENTRY INTO FORCE	NATIONAL FOCAL POINT	
Jordan	A permit must be obtained but no information on a specific text	October 12, 2014	Mr. Bilal Qtishat P.O. Box 1408 Amman 11941 Director Department Nature Protection Directorate Ministry of Environment bqtishat@yahoo.com +962 65560113	
Lebanon	N/A	January 18, 2018	Ms. Lara Samaha Lazarieh Building P.O.Box 11-2727 Beirut Head Department Department of Conservation of Natural Wealth Organization Ministry of Environment I.samaha@moe.gov.lb +961 1 976 555 ext 417	
Egypt	N/A	October 12, 2014	Mr. Ossama El-Tayeb 30 Maadi Zerae Road, 7th floor Maadi Cairo Scientific Advisor Department Nature Conservation Sector Egyptian Environmental Affairs Agency omtayebom@gmail.com; drfoudamos@gmail.com +202 3336 3222, +2010 607 7374	

2/4 – The Nagoya Protocol within MediLab Secure

COUNTRY	STATUS	ENTRY INTO FORCE	NATIONAL FOCAL POINT
State of Paslestine	N/A	N/A	N/A
Lybia	N/A	N/A	Mr. Hamzah Abdulkaber Ahmed P.O. Box 83618 Al Gheran, Janzur Road Tripoli Organization Ministry of Environment hamzanoury986@gmail.com +218 926964911

NON-PARTY




3/4 – Date of genetic resources collection



[https://www.cbd.int/abs/nagoya-protocol/signatories/]


Date to remember:
October 12th **2014**




DATE OF ENTRY INTO FORCE OF THE PROTOCOL IN EACH PARTY



4/4 – Access request and benefit-sharing






Monetary	Non-monetary		
 Access fees/fee per sample collected or otherwise acquired Up-front payments; Milestone payments; Payment of royalties Licence fees in case of commercialization Research funding Joint ownership of relevant intellectual property rights. 	 Sharing of research and development results Collaboration and contribution in scientific research and development programs Collaboration, cooperation and contribution in education and training; Strengthening capacities for technology transfer; Institutional capacity-building 		



4/4 – Traceability is key!

Ma ériel: XXX	<u>a diliqence nëc</u>	essaire		
Pays de collecte init	iale du Matérie	l:	Année de collecte initiale :	
Autorisation du pays d'origine à accéder au Matérie	□Non	itions d'utilisatio □Oui Autorité ayant	ion nt délivré l'autorisation :	
	NA NA	Autorisation	of Compliance) □PIC (Prior Informed 0	Recognized Certificates Consent)
	NA	Conditions d'utilisation	Champ d'utilisation autorisé (ex.: utilisaticommerciale): Autorisation de transfert (ex.: droit au transfà un tiers):	
	NA	Conditions convenus d'un commun accord (MAT)	□Oui □Non Date de délivrance : Conditions et modalités du partage des avantages (ex. : type de partage des avantages) :	

Annexe X – Informations relatives à l'accès au Matériel et au partage des avantages découlant de son utilisation




Track sheet Excel table Software



How to implement ABS requirements in my institution?

- Process institution policy Sample managment
- Access request email template
- Tracking sheet
- Contracts:
 - ✓ Material Deposit Agreements
 - ✓ Material Transfer Agreements...













1/6 – Surveillance activities – R&D







Prospective collection of genetic resources

- •Email to National Focal Point of the country of origin
- •Mention of the surveillance objective
- •Transfer to another lab (abroad)

Transfer of genetic resources

- •In case of research project or focal point requirement, conclusion of an MTA:
- · costs of transfer
- intellectual property and publications
- acces and benefit-sharing obligations

Use of genetic resources


- •Within the scope authorized by the National Competent Authority
- •Keep record of use (e.g. tracking sheet) for future benefit-sharing and secondary transfers



2/6 – Technical exchange in diagnostic activities








• For the applicable legal duration of diagnostic samples



3/6 – Diagnostic & technical training




4/6 - EQA




Genetic resource is a tool here and not the purpose of the study

If no destruction and secondary use, regularization of utilization





5/6 – Transfer of GR for conservation purposes





6/6 – Data Sequencing Information (DSI)



ISSUE: DEFINING A FRAMEWORK

What type of data is concerned by this notion? Only newly sequenced ones?

How to link DSI to a tangible genetic resource and a specific country?

No consensus on the determination of the exact geographical origin of DSI

Important matter COP 15

DSI regime in the future WHO treaty? (2024)

Numerous legal and scientific position papers on the subject

Potential solution: multilateral system, open access, common fund

ISSUE: CONFLICTING INTERETS

Tangible resource = DSI = synthetic resource

→ The values of the Protocol would be undermined if DSI excluded

BUT

Considering DSI as GR not feasible in practice, especially for big data projects

→ Goes against Open Data policies imposed by funders, aren't they already a benefit-sharing for all?

What do you think?



Thank you for your attention

Contacts:

- cindy.diasvilela@pasteur.fr
- cloe.giquel@pasteur.fr

Nagoya Protocol contacts at Institut Pasteur:

dj-apa@pasteur.fr



Institut Pasteur 25-28 rue du docteur Roux 75724 Paris Cedex 15

